Turning 65 today means something very different than it did 30 years ago. Today’s seniors experienced the antibiotic revolution, the cardiac care breakthrough, and the dawn of cancer therapies that weren’t available during their parents’ time. Those breakthroughs were made possible by decades of investment in medical research and an innovation ecosystem that turns scientific discovery into lifesaving medicines. That system has made the United States the world’s leader in medical innovation, but that leadership is no longer guaranteed.Emerging global competitors, particularly China, are investing aggressively in biomedical innovation and rapidly accelerating the pace of drug development. China now moves from molecule discovery to human clinical trials almost 70% faster than any other country, underscoring the speed at which the global innovation race is evolving. If the U.S. continues its current path, it risks ceding its leadership in medical innovation and denying the next generation of seniors the same lifesaving advances today’s older Americans have benefited from.America doesn’t risk losing its leadership because our scientists are less capable than China’s. We risk losing it because our own regulatory system is making it harder to bring new discoveries to patients. A new report identifies a specific bottleneck threatening America’s leadership: unnecessary delays in the Food and Drug Administration approval process. While we can all agree that patient safety must remain the priority, much of the lengthy FDA approval timeline is driven not by safety reviews but by prolonged effectiveness evaluations. As a result, therapies that have already demonstrated they are safe can remain unavailable to patients for years while additional efficacy data is collected.